Rosacea-Pipeline Review, H1 2015

Rosacea-Pipeline Review, H1 2015

  • Products Id :- GMDHC6606IDB
  • |
  • Pages: 94
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Rosacea-Pipeline Review, H1 2015


Global Markets Direct's, 'Rosacea-Pipeline Review, H1 2015', provides an overview of the Rosacea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rosacea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Rosacea

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Rosacea and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Rosacea pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Rosacea

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Rosacea Overview 8

Therapeutics Development 9

Pipeline Products for Rosacea-Overview 9

Pipeline Products for Rosacea-Comparative Analysis 10

Rosacea-Therapeutics under Development by Companies 11

Rosacea-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Rosacea-Products under Development by Companies 15

Rosacea-Companies Involved in Therapeutics Development 17

Allergan, Inc. 17

Amorepacific Corporation 18

Celgene Corporation 19

Celtaxsys, Inc. 20

Cutanea Life Sciences 21

Delenex Therapeutics AG 22

Dermira Inc. 23

Foamix Pharmaceuticals Ltd. 24

Hovione FarmaCiencia SA 25

Kasiak Research Pvt. Ltd. 26

Merz Pharma GmbH & Co. KgaA 27

Promius Pharma, LLC 28

RestorGenex Corporation 29

TWi Pharmaceuticals, Inc. 30

Valeant Pharmaceuticals International, Inc. 31

Rosacea-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

AC-701-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

ACUD-1-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

apremilast-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

CTX-4430-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

DLX-1008-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

DRM-02-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

GM-1111-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

incobotulinumtoxin A-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

minocycline-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

minocycline Gel-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

omiganan pentahydrochloride-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

oxymetazoline hydrochloride-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

P-529-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

PAC-14028-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

PDI-320-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Refaglo-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

SIG-990-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Small Molecules for Cancer, Rosacea and Psoriasis-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

tetracycline MR-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Rosacea-Recent Pipeline Updates 69

Rosacea-Dormant Projects 84

Rosacea-Discontinued Products 86

Rosacea-Product Development Milestones 87

Featured News & Press Releases 87

Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 87

Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 87

Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 88

Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 89

Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 90

Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 90

Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea 91

Mar 16, 2012: Galderma Completes Phase III Trials Of Investigational Drug Targeting Facial Erythema Of Rosacea 91

Oct 20, 2011: Galderma Announces Positive Phase IIb Results For Investigational Compound Targeting Redness Of Rosacea 92

Aug 15, 2011: Argyle Therapeutics Receives Phase II SBIR Grant To Develop SIG990 92

Appendix 93

Methodology 93

Coverage 93

Secondary Research 93

Primary Research 93

Expert Panel Validation 93

Contact Us 93

Disclaimer 94

List of Tables

Number of Products under Development for Rosacea, H1 2015 9

Number of Products under Development for Rosacea-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Development by Companies, H1 2015 (Contd..1) 16

Rosacea-Pipeline by Allergan, Inc., H1 2015 17

Rosacea-Pipeline by Amorepacific Corporation, H1 2015 18

Rosacea-Pipeline by Celgene Corporation, H1 2015 19

Rosacea-Pipeline by Celtaxsys, Inc., H1 2015 20

Rosacea-Pipeline by Cutanea Life Sciences, H1 2015 21

Rosacea-Pipeline by Delenex Therapeutics AG, H1 2015 22

Rosacea-Pipeline by Dermira Inc., H1 2015 23

Rosacea-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 24

Rosacea-Pipeline by Hovione FarmaCiencia SA, H1 2015 25

Rosacea-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 26

Rosacea-Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 27

Rosacea-Pipeline by Promius Pharma, LLC, H1 2015 28

Rosacea-Pipeline by RestorGenex Corporation, H1 2015 29

Rosacea-Pipeline by TWi Pharmaceuticals, Inc., H1 2015 30

Rosacea-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 31

Assessment by Monotherapy Products, H1 2015 32

Number of Products by Stage and Target, H1 2015 34

Number of Products by Stage and Mechanism of Action, H1 2015 36

Number of Products by Stage and Route of Administration, H1 2015 38

Number of Products by Stage and Molecule Type, H1 2015 40

Rosacea Therapeutics-Recent Pipeline Updates, H1 2015 69

Rosacea-Dormant Projects, H1 2015 84

Rosacea-Dormant Projects (Contd..1), H1 2015 85

Rosacea-Discontinued Products, H1 2015 86

List of Figures

Number of Products under Development for Rosacea, H1 2015 9

Number of Products under Development for Rosacea-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 32

Number of Products by Top 10 Targets, H1 2015 33

Number of Products by Stage and Top 10 Targets, H1 2015 33

Number of Products by Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Top 10 Routes of Administration, H1 2015 37

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 38

Number of Products by Top 10 Molecule Types, H1 2015 39

Number of Products by Stage and Top 10 Molecule Types, H1 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Allergan, Inc.

Amorepacific Corporation

Celgene Corporation

Celtaxsys, Inc.

Cutanea Life Sciences

Delenex Therapeutics AG

Dermira Inc.

Foamix Pharmaceuticals Ltd.

Hovione FarmaCiencia SA

Kasiak Research Pvt. Ltd.

Merz Pharma GmbH & Co. KgaA

Promius Pharma, LLC

RestorGenex Corporation

TWi Pharmaceuticals, Inc.

Valeant Pharmaceuticals International, Inc.

Rosacea Therapeutic Products under Development, Key Players in Rosacea Therapeutics, Rosacea Pipeline Overview, Rosacea Pipeline, Rosacea Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]